Fig. 2From: Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosisProportions of patients achieving the no evidence of disease activity (NEDA-3) at the end of the 24-month follow-up according to previous treatment history (n = 196); statistical comparisons were done by the Chi-squared testBack to article page